Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites

Y M Zhang, Hiromi Imamichi, Tomozumi Imamichi et al. · Journal of Virology · 1997 · 323 citations · Full text

Cleavage Site, Immunodeficiencies, Immunology +19

Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors

Louise Doyon, G Croteau, Diane Thibeault et al. · Journal of Virology · 1996 · 296 citations · Full text

Viral Replication, Immunology, Molecular Biology +18

A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism

Monique Nijhuis, Noortje M. van Maarseveen, Stéphane Lastère et al. · PLoS Medicine · 2007 · 166 citations · Full text

Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro

Michael Maguire, Rosario Guinea, Philip Griffin et al. · Journal of Virology · 2002 · 157 citations · Full text

Viral Replication, Immunology, I50v Protease Mutants +18

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

Júlia G. Prado, Terri Wrin, Jeff Beauchaine et al. · AIDS · 2002 · 110 citations